This brand name is authorized in Australia, Austria, Estonia, France, Malta, Spain.
The drug IMUKIN contains one active pharmaceutical ingredient (API):
1
|
UNII
21K6M2I7AG - INTERFERON GAMMA-1B
|
|
It is presumed that interferon gamma-1b increases macrophage cytotoxicity by enhancing the respiratory burst via generation of toxic oxygen metabolites capable of mediating the killing of intracellular micro-organisms. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| L03AB03 | Interferon gamma | L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AB Interferons |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| AU | Pharmaceutical Benefits Scheme | 5769P, 6148N |
| EE | Ravimiamet | 1681332, 1708657 |
| ES | Centro de información online de medicamentos de la AEMPS | 60113 |
| FR | Base de données publique des médicaments | 67401121 |
| MT | Medicines Authority | AA565/39303 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.